The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Proceedings of the National Academy of Sciences of the United States of America - Tập 101 Số 26 - Trang 9861-9866 - 2004
Berkley A. Lynch1, Nathalie Lambeng1, Karl Nocka1, Patricia Kensel-Hammes1, Sandra Bajjalieh1, Alain Matagne1, B. B. Fuks1
1Departments of Molecular and Cellular Biology and Bioinformatics and Target Discovery, UCB Research Inc., 840 Memorial Drive, Cambridge, MA 02139; Departments of In Vitro Pharmacology and CNS Pharmacology, UCB S.A., Pharma Sector, Chemin du Foriest, B-1420 Braine L'Alleud, Belgium; and Department of Pharmacology, University of Washington, D429 HSB, Box 357280, Seattle, WA 98195-7280

Tóm tắt

Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent molecular mass of ≈90 kDa. Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding. LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding. No binding was observed to the related isoforms SV2B and SV2C. Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain. Finally, there is a strong correlation between the affinity of a compound for SV2A and its ability to protect against seizures in an audiogenic mouse animal model of epilepsy. These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs. Further, these results indicate that proteins involved in vesicle exocytosis, and SV2 in particular, are promising targets for the development of new CNS drug therapies.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199011223232107

10.1592/phco.21.17.1375.34432

10.1093/ajhp/58.13.1195

10.1046/j.1528-1157.2001.05404.x

10.1016/S0014-2999(98)00410-5

10.1006/phrs.2000.0689

10.1097/00001756-200307010-00017

Löscher, W., Hönack, D. & Rundfeldt, C. (1998) J. Pharmacol. Exp. Ther. 284, 474-479.9454787

Margineanu D. G. & Klitgaard H. (2002) in Antiepileptic Drugs eds. Levy R. H. Mattson R. H. Meldrum B. S. & Perucca E. (Lippincott Williams & Wilkins Philadelphia) 5th Ed. pp. 419-427.

10.1038/sj.bjp.0704766

10.1016/0014-2999(95)00436-O

10.1016/j.ejphar.2003.08.033

10.1083/jcb.100.4.1284

10.1523/JNEUROSCI.14-09-05223.1994

10.1016/j.ejphar.2003.08.032

10.1073/pnas.96.26.15268

10.1016/S0896-6273(00)81046-6

10.1083/jcb.96.5.1374

10.1074/jbc.M000674200

Chapman, A. G., Croucher, M. J. & Meldrum, B. S. (1984) Arzneimittelforschung 34, 1261-1264.6542784

10.1016/0092-8674(92)90319-8

10.1038/35087000

10.1126/science.1519064

10.1074/jbc.271.44.27770

10.1073/pnas.0336914100

10.1016/S0168-9525(03)00167-7

10.1007/PL00005097

10.1038/sj.bjp.0704141

Thông tin
Thông tin xuất bản

Proceedings of the National Academy of Sciences of the United States of America

Tập 101 Số 26

9861-9866

Thông tin tác giả